Chicago, ILNCT07225361Now EnrollingIRB Ready

Multiple Sclerosis Clinical Trial in Chicago, IL

Access cutting-edge multiple sclerosis treatment through this phase 4 clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by Northwestern University

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access multiple sclerosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related multiple sclerosis treatment provided free

Apply for This Chicago Location

Check if you qualify for this multiple sclerosis clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Multiple Sclerosis Study in Chicago

In this prospective, open-label, single-arm, single-institution trial, the investigators will accomplish the following two aims: 1. study the safety and tolerability of Ublituximab (Briumvi) twice annually in participants with early MS over a treatment observation period of \~12 months. 2. study the pre- and post-treatment change in plasma neurofilament light chain, tested at baseline pre-Ublituximab treatment, and q24 weeks for 96 weeks post Ublituximab treatment initiation.

Sponsor: Northwestern University

Who Can Participate

Inclusion Criteria

Meet 2024 Criteria for Multiple Sclerosis (Montalban et al.) as confirmed by a neurologist; Includes dissemination in space in two of five topographies (with optic nerve included) and/or biomarker evidence such as positive cerebrospinal fluid oligoclonal bands, elevated kappa free light chains, at least six central vein lesions, or at least one paramagnetic rim lesion;
Adult age 18-70 years,
EDSS \<2.5,
Able to provide individual informed consent,
MRI brain available to confirm the diagnosis of MS with fewer than 10 demyelinating lesions,
Diagnosis of MS within the past \<5 years,
Planning to start Ublituximab for the treatment of relapsing MS,

Exclusion Criteria

Prior exposure to Mavenclad, Lemtrada, Cyclophosphamide, stem cell transplant or related bone marrow suppressive treatment,
Prior exposure to other B-cell depleting agent including Ocrelizumab, Rituximab, Ofatumumab, and Inebilizumab.
Current clinical trial participant,
Unable to speak a language for which translation can be found in the hospital system,
Unclear documentation of MS diagnosis or prior or current MS treatment,
Recent major surgical procedure in the past 6 months,
History of life-threatening infusion reaction on Ublituximab or prior anti-CD20 therapy
Active hepatitis B virus (HBV) confirmed by positive results for Hepatitis B surface antigen (HBsAg) and anti-HBV tests.
Receipt of any live of live-attenuated vaccines within 4 weeks prior to first drug product administration
Moribund status,
Unable to provide consent voluntarily due to reasons of capacity or other reasons (e.g. incarcerated, etc.),
Unwilling to undergo blood draws,
Unable to access Ublituximab through clinical coverage throughout the full 96-week treatment study period,
Unable to complete the study activities for any reason as deemed by the study investigator.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT07225361) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Multiple Sclerosis Treatment Options in Chicago, IL

If you're searching for multiple sclerosis treatment options in Chicago, IL, this clinical trial (NCT07225361) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this phase 4 clinical trial. You'll receive care from experienced multiple sclerosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all multiple sclerosis clinical trials near you to find additional studies recruiting in your area.

More Multiple Sclerosis Trials in Chicago, IL

See all multiple sclerosis clinical trials recruiting in Chicago — not just this study.

Browse Multiple Sclerosis Trials in Chicago →

Browse More Trials by Condition

Multiple Sclerosis TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL